Aptuit teams with Icagen for assay and ion channel knowhow

By Gareth Macdonald contact

- Last updated on GMT

Label-free tech part of driver for Icagen deal says Aptuit (picture: iStock/DenisLarkin)
Label-free tech part of driver for Icagen deal says Aptuit (picture: iStock/DenisLarkin)

Related tags: Cell membrane, Ion channel

Aptuit has partnered with Icagen in a marketing deal focused on the CRO’s label-free assay knowhow.

The deal – financial terms of which were not made public – will see the contract research organsations (CRO) offer combined research services, with Icagen contributing its transporter assay capabilities and Aptuit providing its discovery services.

Aptuit cited Icagen’s collection of ion channel cell lines and its proprietary XRpro platform as key drivers for the agreement.

The XRpro technology uses x-ray fluorescence for high throughput analysis of plasma membrane ion channels and transporters, including nonelectrogenic symporters and antiporters.

The use of fluorescence eliminates some of the special handling requirements that are needed when using dye, fluorophores, and radiolabel-based assay technologies.


Aptuit is not the only preclinical services firm to have been attracted by Icagen’s assay development knowhow.

In January, Albany Molecular Research Inc (AMRI) signed a three-year, co-marketing and development agreement with Icagen and also cited the XRpro system as a highlight.

AMRI’s deal with Icagen followed just a year after the US-headquartered contractor paid Aptuit $60m for an aseptic manufacturing site in Glasgow, UK and solid-state and analytical chemistry services site in West Lafayette, Indiana.

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

show more

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Follow us


View more